US Patent 9,517,220: Bromfenac 0.07% Ophthalmic Patent Scope, Expiration, and Generic Risk

US Patent 9,517,220 protects a specific method of using bromfenac ophthalmic solution at 0.07% w/v. The claims combine a low bromfenac concentration, a near-neutral pH, 1.0% povidone, topical ocular administration, and a therapeutic-performance limitation requiring efficacy comparable to or better than a higher-strength bromfenac product. The patent is directed primarily to the Prolensa-type formulation and dosing regimen, rather than to bromfenac generally.

The principal commercial risk is a generic or competing product that copies the formulation and is labeled for the claimed post-cataract treatment regimen. A product using a different bromfenac concentration, pH, excipient profile, or labeled indication may avoid literal infringement, although induced-infringement and equivalents theories remain relevant.

What does US Patent 9,517,220 protect?

US 9,517,220 protects a method of treating an ocular condition by administering bromfenac as the only active pharmaceutical ingredient in a topical ophthalmic composition containing:

Claim limitation	Scope
Active ingredient	Bromfenac as the only active
Bromfenac concentration	0.07% w/v
Povidone	1.0%
pH	At least 6.0 and below 8.0
Administration	Topical administration to the eye
Therapeutic result	Same or better therapy than a higher bromfenac concentration
Penetration result	Enhanced bromfenac penetration into ocular tissue
Core clinical use	Treatment of an ocular condition, particularly post-cataract pain and inflammation

Claim 1 is the broadest independent claim. It is not a composition claim. It requires an act of treatment involving the specified formulation and a result involving penetration and therapeutic performance.

The claim does not require a particular bottle, preservative system, dosing frequency, surgery, disease, or ocular tissue. Those limitations appear in dependent claims.

How do the dependent claims narrow the patent?

The dependent claims divide into pH, excipient, disease, dosing, pharmacokinetic, and comparator limitations.

pH limitations

Claims 2 through 8 narrow the formulation to a pH range or individual pH values:

Claim	pH limitation
2	At least 7.0 and no more than 7.8
3	pH 7.0
4	pH 7.1
5	pH 7.2
6	pH 7.3
7	pH 7.4
8	pH 7.5

Claims 3 through 8 are unusually specific. A formulation tested or labeled at pH 7.0 through 7.5 may fall within multiple overlapping claim sets. The pH values are formulation parameters that can be measured directly, making them relatively straightforward to evaluate in an infringement investigation.

The upper limit of pH below 8.0 in claim 1 distinguishes the claimed method from a bromfenac 0.09% formulation at pH 8.3, which is expressly used as the comparator in claim 18.

Preservative and excipient limitations

Claims 9 and 10 cover formulations containing one or more of:

Tyloxapol
Sodium sulfite
Benzalkonium chloride

Claim 10 further specifies:

Tyloxapol at 0.01% to 0.5%
Benzalkonium chloride at no more than 0.01%
Sodium sulfite without a stated concentration limit

These claims create narrower formulation positions around common ophthalmic excipients. A generic product may avoid claims 9 and 10 by omitting the listed excipients, using an alternative surfactant or antioxidant, or using a preservative-free delivery system. That design-around would not necessarily avoid claim 1 if the product still satisfies the 0.07%, pH, povidone, and treatment-result limitations.

What ocular conditions are covered?

Claim 11 lists a broad range of ocular conditions, including:

Meibomianitis and blepharitis
Uveitis and iritis
Conjunctival and eyelid hyperemia
Keratitis, scleritis, and ocular rosacea
Wet age-related macular degeneration
Diabetic retinopathy and diabetic macular edema
Central and branch retinal vein occlusion
Allergic, viral, and bacterial conjunctivitis
Dry eye
Anterior chamber inflammation
Surgical trauma
Chemical, radiation, and thermal burns
Foreign-body penetration

Claim 14 separately covers an ocular inflammatory condition. Claim 12 focuses on post-cataract treatment of pain, inflammation, or both.

The condition list is broad, but practical infringement depends on the accused product's use, labeling, promotion, and actual administration. A generic applicant that obtains approval only for a non-patented indication may reduce direct label-based risk. That strategy does not eliminate risk if the patented post-cataract use remains on the label or the manufacturer actively encourages the use.

What dosing regimen does the patent cover?

Claim 13 covers once-daily administration beginning before surgery and continuing once daily through day 14 after surgery. This is a commercially important limitation because once-daily dosing is a central differentiation for low-concentration bromfenac products.

Claim 15 covers administration as needed. Claim 12 covers post-cataract surgery treatment without requiring the exact day-14 schedule.

The claims therefore cover multiple dosing positions:

A defined perioperative regimen.
Postoperative treatment generally.
As-needed administration.
Treatment of ocular inflammation independent of a specified surgery.

A generic label that includes once-daily dosing before surgery through postoperative day 14 presents materially greater risk than a label limited to a different schedule, subject to the FDA's labeling requirements and the patent's method-of-use claims.

What is the significance of the enhanced-bioavailability claims?

Claims 16 and 17 distinguish between enhanced bromfenac bioavailability in:

Anterior-segment ocular tissue.
Posterior-segment ocular tissue.

These claims add a tissue-location limitation to the base method. The patent therefore reaches beyond a general assertion of clinical efficacy and claims a pharmacokinetic result in a defined ocular compartment.

The result limitation may create litigation issues. An accused manufacturer could dispute whether the claimed enhancement is present, whether it must be demonstrated in every treated patient, and whether the patent provides an objective test for comparing bioavailability. The specification, prosecution history, and expert evidence would be important in construing these limitations.

What does claim 18 add?

Claim 18 states that 0.07% bromfenac can be used without increasing dosing frequency while achieving the same or better efficacy as 0.09% bromfenac at pH 8.3.

This claim is commercially significant because it captures the product-positioning proposition behind a low-dose, once-daily bromfenac product. It requires comparison with a particular higher-strength formulation and pH. The claim is narrower than claim 1 because it includes:

No increase in dosing frequency.
Comparison with 0.09% bromfenac.
Comparator pH of 8.3.
Same or better efficacy.

A product using 0.09% bromfenac, a different comparator formulation, or a different dosing schedule may have arguments against literal infringement of claim 18. Those differences would not necessarily avoid claims 1 through 17.

When does US Patent 9,517,220 lose exclusivity?

The patent issued on December 13, 2016. Its enforceable term is generally calculated under the modern United States patent-term rule as 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and any applicable disclaimer or correction.

Public patent records commonly associate the patent with a 2013 priority position, producing a nominal expiration in 2033. The exact enforceable expiration date should be taken from the USPTO patent-term calculation and any Orange Book listing applicable to the approved product. Patent-term adjustment can move the date beyond the basic 20-year calculation. The patent does not receive biologic-style regulatory exclusivity because bromfenac is a small-molecule ophthalmic drug.

Exclusivity item	Relevance
US 9,517,220 patent	Method-of-use protection for bromfenac 0.07%
FDA approval	Prolensa was approved as bromfenac ophthalmic solution 0.07%
New chemical entity exclusivity	Not applicable to this later formulation approval
Pediatric exclusivity	Must be checked against the product's FDA record
Patent-term adjustment	Can affect the final expiration date
Patent-term extension	Not assumed for this ophthalmic product

The patent's value is therefore concentrated in method-of-use protection, not in a basic chemical patent covering bromfenac itself.

What is the Orange Book status of US 9,517,220?

The relevant Orange Book question is whether US 9,517,220 is listed against the approved bromfenac 0.07% product and whether the listed claims correspond to an approved method of use.

A listed method-of-use patent can support a Paragraph IV certification by an abbreviated new drug application applicant. The applicant may certify that the patent is invalid, unenforceable, or will not be infringed, or may submit a section viii statement seeking approval only for unpatented uses.

For this patent, the central Orange Book issues are:

Whether the patent is listed for the 0.07% bromfenac product.
Whether the approved labeling includes post-cataract pain or inflammation.
Whether the labeling includes once-daily preoperative and postoperative dosing.
Whether the patent's listed use corresponds to the FDA-approved indication.
Whether the patent remains unexpired when an ANDA is approved.

Orange Book listing does not establish patent validity. It determines the FDA's role in the ANDA certification and 30-month-stay framework under the Hatch-Waxman Act.

Which generic entry strategies create the greatest risk?

The highest-risk ANDA would seek approval for a product that matches the following profile:

Risk factor	High-risk position
Concentration	0.07% bromfenac
Povidone	1.0%
pH	7.0 to 7.5
Indication	Post-cataract pain and inflammation
Dosing	Once daily before surgery through day 14
Labeling	Includes the patented postoperative use
Comparator positioning	Claims equal or superior efficacy to 0.09% bromfenac

Lower-risk design options include:

A different bromfenac concentration.
A pH at or above 8.0, if clinically and regulatorily acceptable.
A formulation without 1.0% povidone.
A different dosing frequency.
A label omitting the patented use through a section viii carve-out.
A different product architecture, such as a preservative-free container system.

These strategies may create commercial or regulatory disadvantages. A section viii carve-out is only effective if the FDA-approved labeling can omit the patented indication without making the product unsuitable for approval or commercially nonviable.

Are biosimilar issues relevant?

No. Bromfenac is a chemically synthesized small molecule, not a biologic. The relevant pathway is an ANDA under section 505(j), not a biosimilar application under the Public Health Service Act.

The principal entry mechanisms are:

Paragraph III certification, accepting patent expiration.
Paragraph IV certification, challenging patent validity, enforceability, or infringement.
Section viii statement, carving out a patented method of use.
A 505(b)(2) application for a materially different formulation or clinical use.

A 505(b)(2) applicant may still face patent litigation, but its regulatory and clinical strategy differs from a conventional generic ANDA.

What patent litigation or settlement issues matter?

A Paragraph IV notice concerning an Orange Book-listed method-of-use patent can trigger patent litigation by the listed patent owner or NDA holder. If suit is filed within the statutory period, FDA approval may be stayed for up to 30 months, subject to statutory exceptions and court developments.

For US 9,517,220, litigation risk would focus on:

Whether the accused product contains 0.07% bromfenac.
Whether it contains 1.0% povidone.
Whether its pH falls between 6.0 and below 8.0.
Whether the label induces the claimed post-cataract use.
Whether the claimed penetration and efficacy results are met.
Whether the patent is valid under written-description, enablement, indefiniteness, anticipation, or obviousness standards.

A settlement could permit an agreed launch date before patent expiration. The commercial effect would depend on whether the settlement includes a license, supply arrangement, authorized-generic commitment, or restrictions on the label. No settlement terms should be inferred solely from the patent's existence or an Orange Book listing.

How strong is the patent estate?

US 9,517,220 is strongest against an exact or near-exact copy of the Prolensa-type formulation and dosing regimen. Its principal strengths are measurable formulation limitations and a clinically specific once-daily use.

Its principal vulnerabilities are the functional limitations:

Enhanced penetration.
Same or better therapy.
Enhanced bioavailability.
No increase in dosing frequency.
Comparison with a 0.09% bromfenac product at pH 8.3.

Those limitations may support noninfringement arguments or validity challenges if the patent does not clearly define testing methods, comparative standards, or the required degree of enhancement.

The estate is weaker against a formulation that changes multiple variables at once, particularly concentration, pH, povidone content, and labeled indication. It is stronger where the accused product reproduces the full formulation and the label directs once-daily postoperative use.

How does US 9,517,220 compare with basic bromfenac patents?

The patent should be distinguished from earlier patents covering bromfenac chemistry, ophthalmic compositions, stability, or broad therapeutic use. US 9,517,220 does not appear, from the stated claims, to cover:

The bromfenac molecule itself.
Every bromfenac ophthalmic formulation.
Every concentration of bromfenac.
Oral, injectable, or non-ocular bromfenac use.
A composition standing alone without the claimed treatment method.

Its commercial function is to extend protection around a lower-dose ophthalmic formulation and its clinical administration. The relevant freedom-to-operate review must therefore examine both this method patent and any earlier composition, formulation, manufacturing, and packaging patents.

Key Takeaways

US 9,517,220 is a method-of-treatment patent centered on 0.07% bromfenac ophthalmic solution.
The core formulation requires 1.0% povidone and pH of at least 6.0 but below 8.0.
Claims 2 through 8 create specific protection for pH values from 7.0 through 7.5.
Claim 13 targets once-daily dosing before cataract surgery through postoperative day 14.
Claim 18 directly compares the low-dose method with 0.09% bromfenac at pH 8.3.
The patent does not cover bromfenac or all bromfenac formulations.
The highest-risk generic would copy the 0.07%/1.0% povidone formulation and retain the post-cataract once-daily indication.
A section viii carve-out or material formulation change may reduce infringement risk.
The patent's nominal term extends into approximately 2033, subject to the official USPTO term calculation and any applicable adjustment.
Litigation would likely focus on label-induced infringement and the definiteness, enablement, and proof requirements for the functional performance limitations.

FAQs

Can a generic bromfenac product avoid US 9,517,220 by using 0.09% bromfenac?

Possibly. A 0.09% product would not literally satisfy the 0.07% concentration limitation, but it could implicate other patents covering bromfenac compositions, dosing, or ophthalmic use.

Does changing the pH to 8.3 avoid the patent?

It may avoid the pH limitation in claim 1, which requires a pH below 8.0. The product would still require a separate review against other patents and any infringement theory based on equivalents.

Does the patent cover Prolensa as a composition?

The stated claims are method claims. They cover specified administration of the formulation, not the composition in isolation.

Can a generic obtain approval without the post-cataract indication?

A generic may seek a section viii carve-out for a patented method of use if the FDA determines that the remaining labeling supports approval. The feasibility depends on the approved labeling and FDA's treatment of the indication.

Is enhanced ocular penetration required to prove infringement?

The limitation appears in the claims and may require proof. The legal effect depends on claim construction, the patent specification, prosecution history, and the evidentiary method used to establish the claimed result.

References

U.S. Patent No. 9,517,220, Methods of treating ocular conditions with bromfenac (2016).
U.S. Food and Drug Administration. (2013). Prolensa (bromfenac ophthalmic solution) 0.07% prescribing information. FDA.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.
U.S. Patent and Trademark Office. (n.d.). Patent term adjustment and patent term calculation resources. USPTO.
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bausch And Lomb	PROLENSA	bromfenac sodium	SOLUTION/DROPS;OPHTHALMIC	203168-001	Apr 5, 2013	AB	RX	Yes	Yes	9,517,220	⤷ Start Trial				TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT SURGERY	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2852995	⤷ Start Trial
European Patent Office	2765988	⤷ Start Trial
European Patent Office	4491170	⤷ Start Trial
Spain	2992712	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,517,220

Which drugs does patent 9,517,220 protect, and when does it expire?

Summary for Patent: 9,517,220